Repurposing Licensed Drugs with Activity Against Epstein–Barr Virus for Treatment of Multiple Sclerosis: A Systematic Approach
Year: 2025
Type: article
Source: CNS Drugs
Authors: Vivien Li, Fiona C. McKay, David C. Tscharke, Corey Smith, Rajiv Khanna, Jeannette Lechner-Scott, William D. Rawlinson, Andrew R. Lloyd, Bruce V. Taylor, Julia M. Morahan, Lawrence Steinman, Gavin Giovannoni, Amit Bar-Or, Michael Levy, Natalia Drosu, Andrew Potter, Nigel Caswell, Lynne Smith, Erin C. Brady, Bruce Frost, Suzanne Hodgkinson, Todd A. Hardy, Simon A. Broadley, the Australian Anti-EBV Drugs for MS Working Group
Institutions: The University of Melbourne, Florey Institute of Neuroscience and Mental Health, Multiple Sclerosis Research Australia, Australian National University, QIMR Berghofer Medical Research Institute, John Hunter Hospital, Hunter Medical Research Institute, University of Newcastle Australia, NSW Health Pathology, UNSW Sydney, Kirby Institute, University of Tasmania, Menzies Institute for Medical Research, Stanford University, Queen Mary University of London, Blizard Institute, University of Pennsylvania, Harvard University, Massachusetts General Hospital, The University of Sydney, Concord Repatriation General Hospital, Griffith University, Gold Coast Hospital
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4406239506